Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCV20
- Development stage
- Preclinical
- Lead developer
- AIM Vaccine Co.
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PCV20 is a 20-valent pneumococcal conjugate vaccine being developed by AIM Vaccine Co. to prevent invasive pneumococcal disease and pneumonia caused by *Streptococcus pneumoniae*. The vaccine is designed to induce serotype-specific antibody responses by conjugating capsular polysaccharides from 20 different serotypes of the bacteria to a carrier protein. This conjugation converts the polysaccharide into a T-cell dependent antigen, enhancing immunogenicity and inducing immunological memory, which is particularly critical for protection in infants and young children. As of early 2024, the candidate is in the preclinical research stage within AIM Vaccine Co.'s bacterial vaccine platform.
- Other names
- 20-valent pneumococcal conjugate vaccinePCV20-AIM Vaccine Co.PCV-20-AIM Vaccine Co.PCV 20-AIM Vaccine Co.
02
Targets
SpCPS1 (Streptococcus pneumoniae capsular polysaccharide serotype 1)10A CPS (Streptococcus pneumoniae serotype 10A capsular polysaccharide)11A CPS (Streptococcus pneumoniae serotype 11A capsular polysaccharide)12F CPS (Streptococcus pneumoniae serotype 12F capsular polysaccharide)CPS14 (Streptococcus pneumoniae capsular polysaccharide serotype 14)15B CPS (Streptococcus pneumoniae serotype 15B capsular polysaccharide)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)19A CPS (Streptococcus pneumoniae serotype 19A capsular polysaccharide)CPS19F (Streptococcus pneumoniae capsular polysaccharide serotype 19F)CPS 22F (Streptococcus pneumoniae serotype 22F capsular polysaccharide)CPS23F (Streptococcus pneumoniae capsular polysaccharide serotype 23F)PPS3 (Streptococcus pneumoniae serotype 3 capsular polysaccharide)33F CPS (Streptococcus pneumoniae serotype 33F capsular polysaccharide)CPS4 (Streptococcus pneumoniae capsular polysaccharide serotype 4)PPS5 (Streptococcus pneumoniae capsular polysaccharide serotype 5)6A CPS (Streptococcus pneumoniae serotype 6A capsular polysaccharide)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)7F CPS (Streptococcus pneumoniae serotype 7F capsular polysaccharide)Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V)
Beyond the preview
Go deeper on PCV20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PCV20.